Marcos Pantarotto

Dr. Marcos Pantarotto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BRBernardo dos Santos Raimundo
Bernardo dos Santos Raimundo
PLPedro Miguel Rodrigues Leitão
Pedro Miguel Rodrigues Leitão
MVManuel Vinhas
Manuel Vinhas
MPMaria Ramos Bárbara de Vasconcelos Pires
Maria Ramos Bárbara de Vasconcelos Pires
LQLaura Bispo Quintas
Laura Bispo Quintas
Pedro D. VazPedro D. Vaz
Pedro D. Vaz
Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Effective screening strategies for early diagnosis that could improve disease prognosis are lacking. Non-invasive breath analysis of volatile organic compounds (VOC) is a potential method for earlier LC detection. This study explores the association of VOC profiles with artificial intelligence (AI) to achieve a sensitive, specific, and fast method for LC detection. Patients and methods: Exhaled breath air samples were collected from 123 healthy individuals and 73 LC patients at two clinical sites. The enrolled patients had LC diagnosed with different stages. Breath samples were collected before undergoing any treatment, including surgery, and analyzed using gas chromatography coupled to ion-mobility spectrometry (GC-IMS). AI methods classified the overall chromatographic profiles. Results: GC-IMS is highly sensitive, yielding detailed chromatographic profiles. AI methods ranked the sets of exhaled breath profiles across both groups through training and validation steps, while qualitative information was deliberately not taking part nor influencing the results. The K-nearest neighbor (KNN) algorithm classified the groups with an accuracy of 90% (sensitivity = 87%, specificity = 92%). Narrowing the LC group to those only in early-stage IA, the accuracy was 90% (sensitivity = 90%, specificity = 93%). Conclusions: Evaluation of the global exhaled breath profiles using AI algorithms enabled LC detection and demonstrated that qualitative information may not be required, thus easing the frustration that many studies have experienced so far. The results show that this approach coupled with screening protocols may improve earlier detection of LC and hence its prognosis.

23 November 2024 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
IRINES ROLIM
INES ROLIM
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
JIJoana Ip
Joana Ip
BNBeatriz Nunes
Beatriz Nunes
RCRicardo Coelho
Ricardo Coelho
CFCarol Farver
Carol Farver

11 February 2026 in Lung Cancer
Verified
Journal Article
Open access
IRINES ROLIM
INES ROLIM
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
MPMarcos Pantarotto
Marcos Pantarotto
ESEric de Sousa
Eric de Sousa
JSJoao Sobral
Joao Sobral
CFCarol Farver
Carol Farver
The tumor-associated microbiome influences cancer development and progression, yet the microbial landscape of small cell lung cancer (SCLC) remains unexplored. Given the absence of SCLC-specific microbiome studies, we conducted an exploratory analysis to describe the bacterial and fungal communities present in SCLC tissue. Using 16S rRNA sequencing, we profiled the bacteriome of lung specimens from SCLC and control cases and observed increased bacterial signal and reduced bacterial diversity in SCLC, accompanied by relative enrichment of Firmicutes and Bacteroidota. Actinobacteria were comparatively underrepresented, resulting in a higher Proteobacteria-to-Actinobacteria ratio, although this difference did not reach statistical significance. At the genus level, SCLC samples were dominated by Pseudomonas, Streptococcus, Haemophilus, and Granulicatella, which together accounted for approximately half of the bacterial community. As a secondary, hypothesis-generating analysis, we examined the mycobiome using ITS sequencing and detected the unexpected presence of the biotrophic plant-pathogenic genus Taphrina in a subset (25%) of SCLC samples. Given the methodological constraints and contamination risks inherent to low-biomass FFPE tissues, this fungal signal is interpreted cautiously and framed strictly as preliminary. This study provides the first descriptive characterization of the lung bacteriome and mycobiome in SCLC using FFPE tissue. The observed alterations in microbial composition, including an unexpected fungal signal, offer hypothesis-generating insights that require validation in larger, prospectively collected cohorts incorporating more comprehensive contamination-control strategies.

8 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DGDaniela Garcez
Daniela Garcez
Ana RodriguesAna Rodrigues
Ana Rodrigues
CTCatarina Travancinha
Catarina Travancinha
MPMarcos Pantarotto
Marcos Pantarotto
PCPaulo Costa
Paulo Costa
MFmaria gabriela fernandes
maria gabriela fernandes
Brain metastases represent a major clinical challenge in the management of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor mutations constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood-brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.

17 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DGDaniela Garcez
Daniela Garcez
Ana RodriguesAna Rodrigues
Ana Rodrigues
CTCatarina Travancinha
Catarina Travancinha
MPMarcos Pantarotto
Marcos Pantarotto
PCPaulo Costa
Paulo Costa
MFmaria gabriela fernandes
maria gabriela fernandes
Brain metastases represent a major clinical challenge in the management of non-small-cell lung cancer, particularly in patients with epidermal growth factor receptor mutations, constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood–brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small-cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.

13 February 2023 in Cureus
Verified
Journal Article
Open access
MPMarcos Pantarotto
Marcos Pantarotto
RBRita Barata
Rita Barata
RCRicardo Coelho
Ricardo Coelho
VSVirginia Sousa
Virginia Sousa
CCCatarina Carvalheiro
Catarina Carvalheiro
FTFernanda Tonin
Fernanda Tonin
Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing and managing a patient under adjuvant ICI treatment, we present the case of a 67-year-old female patient with stage IIIB unresectable, epidermal growth factor receptor (EGFR)-mutated, non-small-cell lung cancer who was initially treated with chemoradiotherapy, followed by immunotherapy with durvalumab. During the course of immunotherapy, the patient presented with madarosis and erythematous and endured skin lesions, in addition to lymphadenopathies and pulmonary infiltrates. She was started on first-line palliative treatment with an EGFR tyrosine kinase inhibitor. After reviewing the case, a multidisciplinary team meeting suggested diagnostic procedures, including a transbronchial needle aspiration from mediastinal lymph nodes. The histologic examination showed chronic systemic inflammation and non-caseating granulomas of the sarcoid type. In this case, palliative treatment was suspended and systemic therapy with prednisolone was initiated. The patient became asymptomatic and the previously observed radiologic abnormalities resolved. This case highlights the importance of early recognition and appropriate treatment of irAEs, mainly because these conditions remain poorly understood and are probably underdiagnosed. Considering differential diagnosis is paramount to guide clinical management, despite curative or palliative treatment intent.